Data from A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
Clinical Cancer Research(2016)
关键词
Neuroendocrine Control
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要